MetaWorks Platforms (OTCMKTS:MWRK) vs. OptimizeRx (NASDAQ:OPRX) Head-To-Head Analysis

MetaWorks Platforms (OTCMKTS:MWRK) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Profitability

This table compares MetaWorks Platforms and OptimizeRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MetaWorks Platforms	N/A	-249.65%	-157.91%
OptimizeRx	-27.41%	-4.92%	-3.41%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MetaWorks Platforms and OptimizeRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaWorks Platforms	0	1	0	0	2.00
OptimizeRx	0	3	6	0	2.67

OptimizeRx has a consensus target price of $9.06, suggesting a potential upside of 56.79%. Given OptimizeRx’s stronger consensus rating and higher possible upside, analysts clearly believe OptimizeRx is more favorable than MetaWorks Platforms.

Volatility & Risk

MetaWorks Platforms has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Earnings and Valuation

This table compares MetaWorks Platforms and OptimizeRx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaWorks Platforms	$410,000.00	3.38	-$5.65 million	($0.08)	-0.18
OptimizeRx	$71.52 million	1.49	-$17.57 million	($1.33)	-4.35

MetaWorks Platforms has higher earnings, but lower revenue than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than MetaWorks Platforms, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

16.1% of MetaWorks Platforms shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 6.1% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

OptimizeRx beats MetaWorks Platforms on 9 of the 14 factors compared between the two stocks.

About MetaWorks Platforms

MetaWorks Platforms, Inc. provides blockchain and Web3 development platform. It offers turnkey set of services for companies to develop and integrate blockchain and cryptocurrency technologies into their business operations. The company provides business development and technical services; blockchain and technology program management services; customer development services; business launch services; and post-business launch support services. The company was formerly known as CurrencyWorks Inc. and changed its name to MetaWorks Platforms, Inc. in August 2022. MetaWorks Platforms, Inc. was incorporated in 2010 and is based in Fairfield, California.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.